ArticleDiscover oncology2025
Advanced machine learning framework for enhancing breast cancer diagnostics through transcriptomic profiling.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Identification of ribosomal stress related signature genes and immune microenvironment analysis in ovarian cancer based on multi-machine learning.Discover oncology · 2026Article
- Interpretable Aging Signatures in Human Retinal Cell Types Revealed by Single-Cell RNA Sequencing and Sparse Logistic Regression.Ophthalmology science · 2026Article
- Article
- Artificial intelligence for triple-negative breast cancer from imaging to multi-omics.Frontiers in oncology · 2026Review
- Integrating Artificial Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions.Current issues in molecular biology · 2025Review
- Prognostic assessment and intelligent prediction system for breast reduction surgery using improved swarm intelligence optimization.Frontiers in medicine · 2025Article
- Machine learning-based diagnostic and prognostic models for breast cancer: a new frontier on the clinical application of natural killer cell-related gene signatures in precision medicine.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study proposes an advanced machine learning (ML) framework for breast cancer diagnostics by integrating transcriptomic profiling with optimized feature selection and classification techniques. MATERIALS AND
methodsA dataset of 1759 samples (987 breast cancer patients, 772 healthy controls) was analyzed using Recursive Feature Elimination, Boruta, and ElasticNet for feature selection. Dimensionality reduction techniques, including Non-Negative Matrix Factorization (NMF), Autoencoders, and transformer-based embeddings (BioBERT, DNABERT), were applied to enhance model interpretability. Classifiers such as XGBoost, LightGBM, ensemble voting, Multi-Layer Perceptron, and Stacking were trained using grid search and cross-validation. Model evaluation was conducted using accuracy, AUC, MCC, Kappa Score, ROC, and PR curves, with external validation performed on an independent dataset of 175 samples.
resultsXGBoost and LightGBM achieved the highest test accuracies (0.91 and 0.90) and AUC values (up to 0.92), particularly with NMF and BioBERT. The ensemble Voting method exhibited the best external accuracy (0.92), confirming its robustness. Transformer-based embeddings and advanced feature selection techniques significantly improved model performance compared to conventional approaches like PCA and Decision Trees.
conclusionThe proposed ML framework enhances diagnostic accuracy and interpretability, demonstrating strong generalizability on an external dataset. These findings highlight its potential for precision oncology and personalized breast cancer diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.